These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18318660)

  • 1. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
    Andersen LM; Wind T; Hansen HD; Andreasen PA
    Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
    Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
    J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.
    Hosseini M; Jiang L; Sørensen HP; Jensen JK; Christensen A; Fogh S; Yuan C; Andersen LM; Huang M; Andreasen PA; Jensen KJ
    Mol Pharmacol; 2011 Oct; 80(4):585-97. PubMed ID: 21719463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
    J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
    Yang SQ; Craik CS
    J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.
    Zhao B; Xu P; Jiang L; Paaske B; Kromann-Hansen T; Jensen JK; Sørensen HP; Liu Z; Nielsen JT; Christensen A; Hosseini M; Sørensen KK; Nielsen NC; Jensen KJ; Huang M; Andreasen PA
    PLoS One; 2014; 9(12):e115872. PubMed ID: 25545505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interconversion of active and inactive conformations of urokinase-type plasminogen activator.
    Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP
    Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
    Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
    J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.
    Xu P; Andreasen PA; Huang M
    Int J Biol Sci; 2017; 13(10):1222-1233. PubMed ID: 29104489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
    Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
    Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.
    Sørensen HP; Xu P; Jiang L; Kromann-Hansen T; Jensen KJ; Huang M; Andreasen PA
    J Mol Biol; 2015 Sep; 427(19):3110-22. PubMed ID: 26281711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides.
    Bøtkjaer KA; Byszuk AA; Andersen LM; Christensen A; Andreasen PA; Blouse GE
    Biochemistry; 2009 Oct; 48(40):9606-17. PubMed ID: 19705874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator.
    Crippa MP
    Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
    Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
    Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
    Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
    J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA.
    Sgier D; Zuberbuehler K; Pfaffen S; Neri D
    Protein Eng Des Sel; 2010 Apr; 23(4):261-9. PubMed ID: 20086040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.